Investors Tighten Grip On Venture Capital

As sources of money dry up, potential backers demand that science startups have prototypes to show off, if not products ready to roll PALO ALTO, CALIF.--For much of the eighties, software engineer Eric Hannah rode the roller coaster of venture capital funding for new high-tech startups in northern California. But after one rocketing success and one crashing failure, he's promised himself never to risk another ride. In fact, one of the things he likes most about the Silicon Valley company he's

Written byTa Heppenheimer
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share


As sources of money dry up, potential backers demand that science startups have prototypes to show off, if not products ready to roll
PALO ALTO, CALIF.--For much of the eighties, software engineer Eric Hannah rode the roller coaster of venture capital funding for new high-tech startups in northern California. But after one rocketing success and one crashing failure, he's promised himself never to risk another ride. In fact, one of the things he likes most about the Silicon Valley company he's now with is that it's not being bankrolled by venture capitalists.

"The problem with venture capital is that it's impatient money," says Hannah, a physicist who is now vice president of engineering at Palo Alto, Calif.-based Savitar. The two-year-old company, which designs software for electronic imaging with an emphasis on high-resolution color, relies on the personal assets of its founder, computer scientist Rudolph Burger.

Not every entrepreneur has sworn ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies